Phase 3 Clinical Trial Confirms
SaNOtize’s Treatment is 99% Effective
Against COVID-19!
On Feb 9, 2022 SaNOtize announced the completion of Phase 3 trial in India for its nitric oxide nasal spray. The trial reached primary endpoint:
Reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours
The double-blind, parallel arm, multicenter study, conducted in 306 patients in non-hospitalized adult patients. NONS was safe and well tolerated by patients. No patients experienced moderate, severe, serious Adverse Events (AE) or death in the study.
Buy Now
